A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine, and the combination of both drugs

J Clin Endocrinol Metab. 1986 Jul;63(1):16-9. doi: 10.1210/jcem-63-1-16.

Abstract

The acute GH inhibitory effects of 50 micrograms SMS 201-995, a somatostatin analog, and 2.5 mg bromocriptine were compared in 17 acromegalic patients. SMS 201-995 suppressed plasma GH levels after 2-6 h to 5 micrograms/liter or less in 10 of these 17 patients, while bromocriptine did the same in only 5 of them. There was much variation in the responsiveness to both drugs in these patients, but the GH-lowering effect of 50 micrograms SMS 201-995 was significantly greater than that of 2.5 mg bromocriptine. SMS 201-995 and bromocriptine together significantly suppressed plasma GH levels in 2 of 3 acromegalic patients who were insensitive to both compounds when tested separately. We conclude that most acromegalic patients respond better to SMS 201-995, while a few patients are more sensitive to the GH-lowering effect of bromocriptine. In addition, the combination of SMS 201-995 and bromocriptine can be of value in a few acromegalic patients who do not respond to either drug alone.

Publication types

  • Comparative Study

MeSH terms

  • Acromegaly / blood
  • Acromegaly / drug therapy*
  • Administration, Oral
  • Adult
  • Bromocriptine / administration & dosage
  • Bromocriptine / therapeutic use*
  • Drug Therapy, Combination
  • Female
  • Growth Hormone / blood*
  • Humans
  • Injections, Subcutaneous
  • Male
  • Middle Aged
  • Octreotide
  • Somatostatin / administration & dosage
  • Somatostatin / analogs & derivatives*
  • Somatostatin / therapeutic use

Substances

  • Bromocriptine
  • Somatostatin
  • Growth Hormone
  • Octreotide